Predictive Oncology Inc Stock Price, News & Analysis

Predictive Oncology (NASDAQ: POAI) has secured a $10 million Securities Purchase Agreement with Yorkville Advisors Global to support its growth initiatives. The company is expanding the availability of its ChemoFx® proprietary live-cell tumor profiling assay in the U.S. and launching in Europe.

ChemoFx leverages the company's database of 150,000 tumor samples across 137 cancer types to predict chemotherapy responses, helping oncologists make better treatment decisions. The company plans to extend beyond gynecological cancers into breast, colon, and lung cancers. Additionally, POAI is advancing its AI-driven drug discovery initiatives, including successful development of machine learning models for ovarian cancer outcomes in collaboration with UPMC Magee-Womens Hospital.

Predictive Oncology (NASDAQ: POAI) has secured a $10 million Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors Global's investment fund. The agreement provides flexible funding access to advance the company's AI-driven drug discovery and repurposing initiatives.

Under the SEPA terms, POAI maintains full control over the timing and amount of stock sales, with no warrants, derivatives, or minimum commitments required. The funding will support ongoing drug discovery, biomarker research, and business development opportunities with biopharmaceutical companies through their AI and machine learning capabilities.

Predictive Oncology (NASDAQ: POAI) has developed exclusive 3D liver toxicity organoid models for Labcorp (NYSE: LH), including human and rat variants, to enhance drug discovery and toxicity testing. These models simulate liver microenvironments to predict drug clearance, transport, and hepatotoxicity. The technology leverages POAI's extensive biobank of 150,000+ frozen tumor samples and complements their AI-driven 2D platform and 3D spheroids. The models demonstrated optimal liver morphology and function through various tests, including cell junction formation and hepatotoxicity measurements. This development aligns with the growing organoid-based platform market, which aims to accelerate drug development while reducing reliance on animal testing.

The Delaware Court of Chancery has denied Renovaro's (RENB) request for an expedited trial in July against Predictive Oncology (NASDAQ: POAI), citing RENB's delay in filing their action. The Court has instead scheduled the trial for November 12-13, 2025. POAI, an AI-driven drug discovery company, strongly maintains that RENB's claims are based on inaccurate allegations and lack merit. The company has expressed its commitment to defending its rights and looks forward to presenting its case in court.

Predictive Oncology (NASDAQ: POAI) has announced significant progress in AI-enabled cancer drug discovery, leveraging its extensive biobank of over 150,000 live cell tumor samples across 137 cancer indications. The company successfully developed predictive tumor response models for 21 previously untested molecules from the University of Michigan, targeting common cancers including breast, colon, and ovarian cancers.

This announcement coincides with Regeneron's $256 million acquisition of 23andMe, highlighting the industry's shift toward data-driven drug discovery. The company's proprietary active machine learning platform enables in silico drug response testing before in vitro confirmation, significantly accelerating development timelines and improving the Probability of Technical Success in drug development.

Predictive Oncology (NASDAQ: POAI) has shared significant progress in its AI-driven drug discovery and biomarker development initiatives. The company has achieved key milestones including: successful development of AI-powered survival prediction models for ovarian cancer in collaboration with UPMC Magee-Womens Hospital, identification of novel cancer biomarkers, and expansion of their ChemoFx® assay into Europe. The company leverages its biobank of 150,000 tumor samples across 137 cancer types to validate AI drug response predictions. Operating in the biomarker discovery market, valued at $14.5 billion in 2024 with projected 19.4% CAGR through 2030, POAI is exploring strategic partnerships and advancing drug repurposing initiatives, having identified three promising candidates for ovarian and colon cancer treatment.

Predictive Oncology (NASDAQ: POAI) reported Q1 2025 financial results with a net loss of $2.3 million on revenue of $110,310. Key developments include identifying three repurposed drug candidates (Afuresertib, Alisertib, Entinosta) for breast and colon cancer through AI/ML analysis, launching ChemoFx® drug response assay in Europe, and selling Skyline Medical assets to DeRoyal Industries. The company ended Q1 with $3.1 million in cash, up from $611,822 in December 2024. Operating expenses decreased across all categories, with G&A expenses down to $1.8 million from $2.3 million YoY. Loss per share improved to $0.32 compared to $0.88 in Q1 2024, while revenue increased significantly from $4,858 in Q1 2024.

Predictive Oncology (NASDAQ: POAI) has developed a novel approach to repurpose abandoned oncology drugs using active machine learning and their biobank of patient-derived tumor cells. The company successfully identified three promising compounds in less than 12 weeks:

1. Afuresertib (Akt inhibitor): Showed strong results in ovarian and colon tumors
2. Alisertib (Aurora A Inhibitor): Outperformed standard care drugs in colon and breast cancer
3. Entinostat (HDAC1/3 inhibitor): Demonstrated strong response in colon samples

The screening method efficiently evaluated these compounds against tumor indications that were previously unexplored. Notably, Alisertib and Entinostat outperformed Oxaliplatin in colon tumor treatment, while Alisertib also showed superior results compared to Ribociclib in breast cancer treatment.

Predictive Oncology (POAI) reported its financial results for Q4 and full-year 2024, posting a $10.8 million loss from continuing operations on revenue of $1.6 million. The company is progressing toward a definitive merger agreement with Renovaro Inc, having received the first tranche of financing to integrate AI/ML platforms and expand operations.

Key developments include the sale of Skyline Medical subsidiary to DeRoyal Industries, partnership with Tecan Group for high-throughput drug screening, and planned European launch of ChemoFx® drug response assay. The company raised over $3.0 million in Q1 2025 through various financing activities.

Financial highlights: Cash position decreased to $734,673 from $8.7 million year-over-year, with stockholder's deficit of $(202,610). Revenue remained relatively flat at $1.62 million compared to $1.63 million in 2023. Operating expenses decreased across all categories, with general and administrative expenses down by $961,025 to $7.42 million.